肿瘤细胞治疗研究
英文原题：CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature.
纳入29项前瞻性研究（265例患者）。
本系统综述旨在评估迄今为止发表的所有关于CAR-T细胞疗法在实体瘤中疗效的前瞻性研究。检索的数据库为PubMed和Google Scholar，检索时间从建库至2021年5月1日。检索式为（嵌合抗原受体）或（CAR-T）或（T-CAR）。共纳入29项前瞻性研究（265例患者）。大多数已发表的临床试验为I期。临床获益在上皮性卵巢癌中为100%，胃肠道肿瘤中为70-82%，间皮瘤中为79%，小细胞肺癌中为63%，肉瘤中为24-67%，前列腺癌中为50-62%，中枢神经系统肿瘤中为45-50%。未观察到严重的CAR-T细胞特异性严重毒性。
This systematic review aims to assess all the prospective studies published to date on the efficacy of CAR-T cell therapy in solid tumors. Databases searched were PubMed and Google Scholar from inception through May 1st 2021. Search query was (Chimeric antigen receptor) or (CAR-T) or (T-CAR). Twenty-nine prospective studies (265 patients) were included. Most published clinical trials are phase I. Clinical benefit was 100% in epithelial ovarian cancer, 70-82% in gastrointestinal tumors, 79% in mesothelioma, 63% in small-cell lung cancer, 24-67% in sarcoma, 50-62% in prostate cancer, and 45-50% in central nervous system tumors. No serious CAR-T cell specific serious toxicities were noted.
MEMBER ACCOUNT
登录成功会直接打开下一页。
